CD8A and neoplasm: Antitumor efficacy was demonstrated in CT26 and 4T1 murine tumor models concomitant with upregulation of IFN-γ signature genes, CD8+ and effector memory tumor-infiltrating lymphocytes, and MHC class I expression on tumor cells, in addition to decreased levels of myeloid-derived suppressor cells [154].